Lumpectomy and Accelerated Partial Breast Irradiation as an Alternative to Mastectomy Following Prior Radiation Therapy
This report details our experience using accelerated partial breast irradiation (APBI) as a component of salvage breast conserving treatment.
Contributors : M Schmidt ; M GehrmannSeries Type : Expression profiling by arrayOrganism : Homo sapiensInterferons are crucial for adaptive immunity and play an important role in the immune landscape of breast cancer. Using microarray-based gene expression analysis, we examined the subtype specific prognostic significance of interferon- γ (IFN-γ) as a single gene as well as an IFN-γ signature covering the signaling pathway in 461 breast cancer patients. Prognostic significance of IFN-γ as well as the IFN-γ signature for metastasis-free survival (MFS) were examined using Kaplan Meier as well as...
Publication date: Available online 20 September 2020Source: The LancetAuthor(s): Serena Di Cosimo
Publication date: Available online 20 September 2020Source: The LancetAuthor(s): Elizabeth A Mittendorf, Hong Zhang, Carlos H Barrios, Shigehira Saji, Kyung Hae Jung, Roberto Hegg, Andreas Koehler, Joohyuk Sohn, Hiroji Iwata, Melinda L Telli, Cristiano Ferrario, Kevin Punie, Frédérique Penault-Llorca, Shilpen Patel, Anh Nguyen Duc, Mario Liste-Hermoso, Vidya Maiya, Luciana Molinero, Stephen Y Chui, Nadia Harbeck
This study also describes the efficacy of biosynthesized AgNPs-GA as anti-proliferative agent against human breast cancer cell lines, MCF-7 and MCF-7/TAMR-1. Our findings indicate that AgNPs-GA possess significant anti-proliferative effects against both the MCF-7 and MCF-7/TAMR-1 cell lines, with inhibitory concentration at 50% (IC50 values) of 2.0 and 34.0 µg/mL, respectively, after 72 h of treatment. An induction of apoptosis was evidenced by flow cytometry using Annexin V-FITC and propidium iodide staining. Therefore, AgNPs-GA exhibited its anti-proliferative activity via apoptosis on MCF-7 and MCF-7/TAMR-1 br...
ConclusionmiR-1976 may serve as a promising non-invasive biomarker for the diagnosis of BC in the future.
Patients with HR+, HER2- breast cancer at high risk of early recurrence on endothelial therapy could highly improve their invasive disease-free survival with adjuvant abemaciclib, a new trial shows.Medscape Medical News
Determining treatment options, as well as the prognosis of patients, may rely on changes in biomarker status during the course of advanced disease progression.Medscape Oncology
Black women with breast cancer may be more likely to experience treatment delays...Read more on AuntMinnie.comRelated Reading: Women with DCIS have 3x the risk of breast cancer death Do breast screening guidelines overlook Black women? Medicaid expansion tied to early breast cancer diagnosis Insurance plays major role in breast cancer disparities Black women still at higher risk of breast cancer death
Combining abemaciclib with hormonal therapy reduces the risk of cancer recurrence by 25% in patients with high-risk early hormone receptor positive (HR+) human epidermal growth factor receptor 2 negative (HER2-) breast cancer, interim analysis of a phase III study has suggested.
MONDAY, Sept. 21, 2020 -- Black women experience longer waits for treatment initiation after a breast cancer diagnosis and prolonged duration of treatment versus White women, according to a study published online Sept. 21 in Cancer. Marc A....